NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th – October 6th, 2020.
The Company will host a booth and will be available online throughout the entire conference to discuss how Daxor’s BVA-100® blood test improves heart failure outcomes and answer questions. New data titled “ Red Cell Volume Phenotypes in Hospitalized Heart Failure Patients” (Poster #132) and “Cost-effectiveness Analysis of Early Blood Volume-Guided Management in Hospitalized Heart Failure Patients” ( Poster #331) will be highlighted in the Poster Hall accompanied by a narrative from the principal investigators.
“The HFSA Annual Scientific Meeting is an exciting venue to increase awareness and utilization of Daxor’s BVA-100® blood test to improve heart failure outcomes and to share new data with key thought leaders and decision makers focused on heart failure research and patient care,” said Michael Feldschuh, President and CEO of Daxor. “Daxor is the global leader in blood volume measurement technology and is engaged in numerous research studies related to the application of BVA technology to improve heart failure outcomes including a randomized control trial, as well as next generation test technology development through contracts awarded by the U.S. Department of Defense.”
Register for the event here: https://hfsa.org/annualscientificmeeting/registration
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner, CORE IR